Our lead compound, LTX-315, is currently being tested in combination with the market approved immunotherapeutic drug KEYTRUDA® (pembrolizumab) in a Phase II study in the US. We are also supporting our licensing partner Verrica Pharmaceuticals in their Phase II trial in patients with basal cell carcinoma.  Lytix Biopharma also has other candidates in the pipeline, including LTX-401, a second-generation molecule developed for treatment of visceral tumors.

Lytix Biopharma’s goal is that the company’s groundbreaking technology will play an important role in cancer treatment in the future.

The company is based on more than 30 years of preclinical and clinical research originated at the Arctic University of Norway, home to one of the leading academic clusters worldwide on generating bioactive drug candidates from naturally occurring host defense peptides.

Our oncolytic molecules are injected directly into one or more available solid tumors. It attacks by binding to the surface of cancer cells, penetrating through the cell membrane and dissolving all compartments of the cancer cell, resulting in a total disintegration and killing of the cancer cell. The destruction causes tumor antigens to be released, which the patient’s immune system recognizes and responds to. The activated immune system starts searching for cancer cells with these tumor antigens and is now able to combat tumors located in other parts of the body.

Please follow Lytix Biopharma's stock announcements by registering your email address here